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Background
Soluble guanylate cyclase (sGC) catalyses the synthesis
of cyclic GMP in response to nitric oxide. The enzyme
is a heterodimer of homologous a and b subunits, each
of which is composed of multiple domains.
Results
We present here crystal structures of a heterodimer of
the catalytic domains of the a and b subunits, as well as
an inactive homodimer of b subunits. This first struc-
ture of a metazoan, heteromeric cyclase provides several
* Correspondence: Opher.gileadi@sgc.ox.ac.uk
Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK
Figure 1 Schematic structures of the catalytic domains of human sGC: A. Homodimer of b subunits, B: Heterodimer of a/b subunits.
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observations. First, the structures resemble known struc-
tures of adenylate cyclases and other guanylate cyclases
in overall fold and in the arrangement of conserved
active-site residues, which are contributed by both subu-
nits at the interface. Second, the subunit interaction sur-
face is promiscuous, allowing both homodimeric and
heteromeric association; the preference of the full-length
enzyme for heterodimer formation must derive from the
combined contribution of other interaction interfaces.
Third, the heterodimeric structure is in an inactive con-
formation, but can be superposed onto an active confor-
mation of adenylate cyclase by a structural transition
involving a 26º rigid-body rotation of the a subunit. In
the modelled active conformation, most active site resi-
dues in the subunit interface are precisely aligned with
those of adenylate cyclase. Finally, the modelled active
conformation also reveals a cavity related to the active
site by pseudo-symmetry. The pseudosymmetric site
lacks key active site residues, but may bind allosteric
regulators in a manner analogous to the binding of for-
skolin to adenylate cyclase. This indicates the possibility
of developing a new class of small-molecule modulators
of guanylate cyclase activity targeting the catalytic
domain.
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